Mumbai, Nov. 17 -- Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India.

Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma(R) whereas Sun Pharma will promote and distribute the therapy as Gimliand(R). AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.

Published by HT Digital Conten...